{"transactions":[{"id":746462,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40560,"kind":"person","name":"Cahill Thomas","position":1,"cik":"0001922939","reported_name":"Cahill Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T20:13:14.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":75000,"derivative":{"exercise_price":3.06,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001628280-26-041553","document":"wk-form4_1780949591.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1922939/000162828026041553/wk-form4_1780949591.xml","form_type":"4"}},{"id":1074937,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40560,"kind":"person","name":"Cahill Thomas","position":1,"cik":"0001922939","reported_name":"Cahill Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:42:47.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":45000,"derivative":{"exercise_price":4.04,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001894562-25-000044","document":"wk-form4_1754440963.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1922939/000189456225000044/wk-form4_1754440963.xml","form_type":"4"}},{"id":1074936,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40560,"kind":"person","name":"Cahill Thomas","position":1,"cik":"0001922939","reported_name":"Cahill Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:42:47.000Z","date":"2025-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.68,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001894562-25-000044","document":"wk-form4_1754440963.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1922939/000189456225000044/wk-form4_1754440963.xml","form_type":"4"}},{"id":1074935,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40560,"kind":"person","name":"Cahill Thomas","position":1,"cik":"0001922939","reported_name":"Cahill Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:42:47.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":39062,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":39062,"derivative":{"exercise_price":4.04,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":39062},"source":{"system":"sec-edgar","filing":"0001894562-25-000044","document":"wk-form4_1754440963.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1922939/000189456225000044/wk-form4_1754440963.xml","form_type":"4"}},{"id":1074934,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40560,"kind":"person","name":"Cahill Thomas","position":1,"cik":"0001922939","reported_name":"Cahill Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:42:47.000Z","date":"2025-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":39062,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":14.83,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":39062},"source":{"system":"sec-edgar","filing":"0001894562-25-000044","document":"wk-form4_1754440963.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1922939/000189456225000044/wk-form4_1754440963.xml","form_type":"4"}},{"id":1121599,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40560,"kind":"person","name":"Cahill Thomas","position":1,"cik":"0001922939","reported_name":"Cahill Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-05T22:11:37.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2026 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":55000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001628280-25-029768","document":"wk-form4_1749161263.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1922939/000162828025029768/wk-form4_1749161263.xml","form_type":"4"}},{"id":1479405,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40560,"kind":"person","name":"Cahill Thomas","position":1,"cik":"0001922939","reported_name":"Cahill Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T20:58:43.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 12, 2025 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":7.68,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001894562-24-000035","document":"wk-form4_1718398714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1922939/000189456224000035/wk-form4_1718398714.xml","form_type":"4"}},{"id":1852745,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40560,"kind":"person","name":"Cahill Thomas","position":1,"cik":"0001922939","reported_name":"Cahill Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T21:51:20.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":39062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 14, 2024 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":39062,"derivative":{"exercise_price":14.83,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":39062},"source":{"system":"sec-edgar","filing":"0001894562-23-000028","document":"wf-form4_168695226752131.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1922939/000189456223000028/wf-form4_168695226752131.xml","form_type":"4"}},{"id":2131747,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40560,"kind":"person","name":"Cahill Thomas","position":1,"cik":"0001922939","reported_name":"Cahill Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2022-10-27T00:00:34.000Z","date":"2022-10-24","kind":"exercise","acquired":false,"shares":5250781,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Newpath Partners, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the \"Preferred Stock\") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the \"Preferred Stock\") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the \"Preferred Stock\") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by Newpath Partners, L.P. (\"Newpath LP\"). Newpath Partners GP, L.P. (\"Newpath GP LP\") is the general partner of Newpath LP. Newpath Partners GP, LLC (\"Newpath GP LLC\") is the general partner of Newpath GP LP. The Reporting Person is a managing member of Newpath GP LLC, and disclaims beneficial ownership of the shares held directly by Newpath LP except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1689005},"source":{"system":"sec-edgar","filing":"0001628280-22-027122","document":"wf-form4_166682881646748.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1922939/000162828022027122/wf-form4_166682881646748.xml","form_type":"4"}},{"id":2131746,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40560,"kind":"person","name":"Cahill Thomas","position":1,"cik":"0001922939","reported_name":"Cahill Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-10-27T00:00:34.000Z","date":"2022-10-24","kind":"exercise","acquired":false,"shares":9999999,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Newpath Partners, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the \"Preferred Stock\") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the \"Preferred Stock\") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the \"Preferred Stock\") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by Newpath Partners, L.P. (\"Newpath LP\"). Newpath Partners GP, L.P. (\"Newpath GP LP\") is the general partner of Newpath LP. Newpath Partners GP, LLC (\"Newpath GP LLC\") is the general partner of Newpath GP LP. The Reporting Person is a managing member of Newpath GP LLC, and disclaims beneficial ownership of the shares held directly by Newpath LP except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3216674},"source":{"system":"sec-edgar","filing":"0001628280-22-027122","document":"wf-form4_166682881646748.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1922939/000162828022027122/wf-form4_166682881646748.xml","form_type":"4"}},{"id":2131745,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40560,"kind":"person","name":"Cahill Thomas","position":1,"cik":"0001922939","reported_name":"Cahill Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T00:00:34.000Z","date":"2022-10-24","kind":"purchase","acquired":true,"shares":400000,"price":17,"value":6800000.0,"ownership":{"direct":false,"nature":"By Newpath Partners, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects shares purchased by Newpath LP in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by Newpath Partners, L.P. (\"Newpath LP\"). Newpath Partners GP, L.P. (\"Newpath GP LP\") is the general partner of Newpath LP. Newpath Partners GP, LLC (\"Newpath GP LLC\") is the general partner of Newpath GP LP. The Reporting Person is a managing member of Newpath GP LLC, and disclaims beneficial ownership of the shares held directly by Newpath LP except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose."}],"balance_after":5305679,"source":{"system":"sec-edgar","filing":"0001628280-22-027122","document":"wf-form4_166682881646748.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1922939/000162828022027122/wf-form4_166682881646748.xml","form_type":"4"}},{"id":2131744,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40560,"kind":"person","name":"Cahill Thomas","position":1,"cik":"0001922939","reported_name":"Cahill Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T00:00:34.000Z","date":"2022-10-24","kind":"exercise","acquired":true,"shares":4905679,"ownership":{"direct":false,"nature":"By Newpath Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the \"Preferred Stock\") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by Newpath Partners, L.P. (\"Newpath LP\"). Newpath Partners GP, L.P. (\"Newpath GP LP\") is the general partner of Newpath LP. Newpath Partners GP, LLC (\"Newpath GP LLC\") is the general partner of Newpath GP LP. The Reporting Person is a managing member of Newpath GP LLC, and disclaims beneficial ownership of the shares held directly by Newpath LP except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose."}],"balance_after":4905679,"source":{"system":"sec-edgar","filing":"0001628280-22-027122","document":"wf-form4_166682881646748.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1922939/000162828022027122/wf-form4_166682881646748.xml","form_type":"4"}}]}